Changrae Kim, DPM
Foot & Ankle Surgery · Bayside, NYNPI 1083022149
Payments from drug & device makers
Across 28 payments — averaging $43.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$410
- Amarin Pharma, Inc.$243
- Stryker$163
- Novo Nordisk$149
- Gilead$125
- Smith+Nephew$59
- plus $75 from 2 others
What the payments were for
- Speaking & faculty fees$1079%
- Food & beverage$1,11791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 14 | $410 |
| Amarin Pharma, Inc. | 2 | $243 |
| Stryker(2 entities) | 3 | $163 |
| Novo Nordisk | 1 | $149 |
| Gilead | 1 | $125 |
| Smith+Nephew | 3 | $59 |
| Integra Lifesciences Corporation | 3 | $58 |
| AbbVie | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$243
- Ozempic$149
- CHARLOTTE$127
- ORTHOLOC 2 LAPIFUSE$127
- Viaflow$127
- ACTISHIELD CF$127
- FUSEFORCE$127
How this compares
$1,224 in reported general payments places this provider in the 35th percentile of 652 foot & ankle surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 914 | $15,679 |
| Ammonium Lactate | 710 | $12,760 |
| Clotrimazole | 234 | $5,618 |
| Diclofenac Sodium | 264 | $5,203 |
| Diclofenac Epolamine | 11 | $3,887 |
| CiclopiroxCiclopirox Olamine | 126 | $3,634 |
| Econazole Nitrate | 60 | $2,266 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 84 | $1,138 |
| Lidocaine | 20 | $931 |
| Mupirocin | 85 | $540 |
| Ciclopirox | 21 | $528 |
| Gabapentin | 105 | $369 |
| Meloxicam | 192 | $294 |
| Cefadroxil | 35 | $276 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 17 | $261 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Bayside
- James McWilliamHarrison$4.7M
- Jonathan DelandNew York$4.1M
- George Vitole Roy$2.5M
- Constantine DemetracopoulosNew York$888K
- Anne JohnsonNew York$815K
- Scott EllisNew York$644K
- John KennedyNew York$613K
- Michael KellerKingston$532K
- Judith BaumhauerRochester$365K
- Edward AzarBrooklyn$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.